Immunizer was already authorized for use in adolescents over 16 years of age in the country, in addition to being used in the age group of 12 to 15 years in the US
Authorities and experts celebrated the approval of the use of vaccine of Pfizer in adolescents over 12 years old in Brazil. The expansion was authorized by the National Health Surveillance Agency this Friday, 11. Pfizer’s vaccine was already authorized for use in adolescents over 16 years of age in the country, in addition to being used in the age group of 12 to 15 years in USA and in Europe. Studies for the application of the immunizing agent in children aged six months to 11 years are ongoing. The coordinator of the Pediatric Infectology Committee of the Brazilian Society of Infectology, Marcelo Otsuka, pointed out that the more people immunized, the lower the circulation and impact of the virus.
“We know that the chance of a child having a more serious, more severe infection, by coronavirus, she is much smaller. But that doesn’t mean it can’t happen. And even with the new variants, what we see is that the number of children who get sick, proportionally, remains the same.” In São Paulo, the vaccination schedule has not yet included young people under 18 years of age. The Secretary of Health of the State of São Paulo, Jean Gorinchteyn, stressed that the federal government needs to be directed. “In order for us to be able to insert these new age groups, we need the deliberation of the Ministry of Health through the National Immunization Plan. In addition to that, we need to receive more immunizations, in the case of Pfizer itself, to be able to provide segment for this age group.”
The municipal secretary of Health, Edson Appeared, was on the same line and said that a signal from higher authorities is needed. “The city is fully prepared to receive Pfizer vaccines. We can store four million doses of Pfizer here in town. We have all the conditions to receive Pfizer inputs.” A new batch of Janssen vaccines should arrive in Brazil in the next few days and governments are preparing a task force to distribute quickly due to the three-month shelf life. This Friday afternoon, Anvisa met with company representatives to discuss the extension of this period. The company’s proposal is to extend it to four and a half months, a measure approved by the regulatory agency of the United States. The Collegiate Board of Anvisa should finalize the analysis of the information presented by Janssen next week.
*With information from reporter Nanny Cox